18.09
-2.74%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aurisco Pharmaceutical Co
Its shares trade on Shanghai under the ticker 605116.SS. It has been listed since 21 September 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.70bn and net income of CN¥449.2m. At that date it held total assets of CN¥4.22bn and shareholders' equity of CN¥2.66bn.
Aurisco Pharmaceutical Co., Ltd. engages in the development and production of pharmaceutical chemicals. The company is headquartered in Taizhou, Zhejiang. The company went IPO on 2020-09-21. The firm's main products are respiratory, cardiovascular, anti-infective and nervous system drugs, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The firm distributes its products in domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 21 Sept 2020
- Employees
- 1,355
- Website
- aurisco.com ↗
Leadership
Pay as last reported
- Ding Jun ChuChief Executive Officer & Director, since 2017
- Xiu Yu WangChief Financial Officer, since 2017
- De Fa ZhangChief Engineer & Production Manager, since 2019
- Fang Fang LiSecretary, since 2017
- Ping JinChairman-Supervisory Board, since 2017
- Zhi An PengChairman, since 2016
- Ding Jun ChuChief Executive Officer & Director, since 2017
- Jian Wen LiDirector, since 2017
- Mei Hua LiuDirector, since 2017
- Pei Jing QiuDirector, since 2017
- Feng Zhen LiuIndependent Director, since 2017
- Li Wei YangMember-Supervisory Board, since 2017
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aurisco Pharmaceutical Co Ltd employs 1,355 full-time employees in Taizhou, Zhejiang.
- The company develops and produces respiratory, cardiovascular, anti-infective, and nervous system drugs.
- Aurisco's main products include flumethasone, fluticasone propionate, and eplerenone APIs.
Weaknesses
- Aurisco Pharmaceutical Co Ltd is headquartered in Taizhou, Zhejiang, a city in China.
- The company's products are distributed only in domestic and overseas markets.
- Aurisco's main products include flumethasone, fluticasone propionate, and eplerenone APIs.
Opportunities
- Aurisco Pharmaceutical Co Ltd has a strong presence in the Chinese pharmaceutical market.
- The company's focus on respiratory, cardiovascular, anti-infective, and nervous system drugs offers growth potential.
- Aurisco's product portfolio includes flumethasone, fluticasone propionate, and eplerenone APIs.
Threats
- Aurisco Pharmaceutical Co Ltd faces competition from other Chinese pharmaceutical companies.
- The company's products are distributed in domestic and overseas markets, which may face regulatory challenges.
- Aurisco's main products include flumethasone, fluticasone propionate, and eplerenone APIs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.